Drug · CHEMBL49
BUSPIRONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. BUSPIRONE. Drugs and targets, record CHEMBL49. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL49
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| HTR1A | 5-hydroxytryptamine receptor 1A | Serotonin 1a (5-HT1a) receptor partial agonist | PARTIAL AGONIST | https://conductscience.org/library/genes/3350 |
Source ChEMBL
Diseases25
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 25Source Open Targets
See all 25 diseasesTrials66
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00053846 | Buspirone in Reducing Shortness of Breath in Patients With Cancer | Phase 2/3 | 432 | 2015-03-20 | buspirone | Its name | ClinicalTrials.gov |
| NCT00895830 | Dose-ranging Study of APD405 in Post-operative Nausea and Vomiting (PONV) | Phase 2 | 257 | 2011-03-24 | buspirone | Its name | ClinicalTrials.gov |
| NCT00875836 | Buspirone Treatment for Marijuana Dependence | Phase 4 | 175 | 2016-03-09 | buspirone | Its name | ClinicalTrials.gov |
| NCT00705003 | Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) | Phase 2 | 142 | 2014-06-18 | buspirone | Its name | ClinicalTrials.gov |
| NCT03587142 | Buspirone for Early Satiety and Symptoms of Gastroparesis | Phase 2 | 96 | 2023-06-15 | buspirone | Its name | ClinicalTrials.gov |
| NCT00731653 | Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD) | Phase 2 | 81 | 2013-12-17 | bci-024 | Its name | ClinicalTrials.gov |
| NCT01821690 | Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression | Phase 4 | 81 | 2026-02-24 | buspirone | Its name | ClinicalTrials.gov |
| NCT01641159 | Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence | Phase 2 | 62 | 2014-12-17 | buspirone | Its name | ClinicalTrials.gov |
| NCT01267292 | Psychopharmacology for Cocaine Dependence - Buspirone | Phase 2 | 50 | 2017-05-04 | buspirone | Its name | ClinicalTrials.gov |
| NCT02132832 | Buspirone, Stress, and Attentional Bias to Marijuana Cues | Phase 2 | 45 | 2017-04-07 | buspirone | Its name | ClinicalTrials.gov |
1 to 10 of 66
See all 66 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Buspirone Hydrochloride vs Placebo: serious adverse events | 3 of 213 | 3 of 219 | 432 | NCT00053846 | Trial comparisons |
| Buspirone vs Placebo: serious adverse events | 0 of 88 | 0 of 87 | 175 | NCT00875836 | Trial comparisons |
| Buspirone vs Placebo: deaths from any cause | 0 of 47 | 0 of 49 | 96 | NCT03587142 | Trial comparisons |
| Buspirone vs Placebo: serious adverse events | 1 of 47 | 1 of 49 | 96 | NCT03587142 | Trial comparisons |
| Buspirone Treatment vs Buspirone Placebo: deaths from any cause | 0 of 41 | 0 of 40 | 81 | NCT01821690 | Trial comparisons |
| Buspirone Treatment vs Buspirone Placebo: serious adverse events | 0 of 41 | 1 of 40 | 81 | NCT01821690 | Trial comparisons |
| Buspirone Treatment vs Buspirone Placebo: Neuropsychiatric Inventory-Irritability Domain - Observer-rated Proportion Improved ≥ 3 Points Baseline to Day-91 | 30 of 38 | 31 of 40 | 78 | NCT01821690 | Trial comparisons |
| Buspirone Treatment vs Buspirone Placebo: Neuropsychiatric Inventory-Aggression Domain - Observer-rated Proportion Improved ≥ 3 Points Baseline to Day-91 | 28 of 38 | 27 of 40 | 78 | NCT01821690 | Trial comparisons |
| Buspirone Plus TAU vs Placebo Plus TAU: serious adverse events | 3 of 35 | 0 of 27 | 62 | NCT01641159 | Trial comparisons |
| Buspirone vs Unmedicated: deaths from any cause | 0 of 26 | 0 of 26 | 52 | NCT03538431 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials117
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials10
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Stroop Color-Word Test | 2 | 2 | ConductCognition |
| Antisaccade Task | 1 | 1 | ConductCognition |
| Cancellation Test | 1 | 0 | ConductCognition |
| Immediate and Delayed Memory Task | 1 | 0 | ConductCognition |
| 1-Back Task | 1 | 0 | ConductCognition |
| 2-Back Task | 1 | 0 | ConductCognition |
| Probabilistic Reversal Learning | 1 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Trail Making Test B | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL49
GET https://conductscience.org/api/drugs/v1/CHEMBL49/diseases?page=2